vimpat
ucb pharma sa - lakosamid - epilepsi - antiepileptika, - vimpat indikeras som monoterapi och kompletterande terapi vid behandling av partiella anfall med eller utan sekundär generalisering hos vuxna, ungdomar och barn från 4 år med epilepsi.
xyrem
ucb pharma ltd - natriumoxybat - cataplexy; narcolepsy - andra nervsystemet droger - behandling av narkolepsi med kataplexi hos vuxna patienter.
evenity
ucb pharma s.a. - romosozumab - osteoporos - läkemedel för behandling av bensjukdomar - evenity är indicerat för behandling av svår osteoporos hos postmenopausala kvinnor med hög risk för fraktur.
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
bimzelx
ucb pharma s.a. - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
cimzia
ucb pharma sa - certolizumab pegol - crohnsjukdom - immunsuppressiva - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia kan ges som monoterapi vid intolerans mot metotrexat eller när fortsatt behandling med metotrexat är olämplig. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.
barcan 100 mg pulver till oral suspension, dospåse
ucb sa pharma sector - aceklofenak - pulver till oral suspension, dospåse - 100 mg - aspartam hjälpämne; aceklofenak 100 mg aktiv substans; sorbitol hjälpämne - aceklofenak
zaxem 10 mg kräm
ucb pharma ab - butenafinhydroklorid - kräm - 10 mg - propylenglykoldikaprylat hjälpämne; natriumbensoat hjälpämne; bensylalkohol hjälpämne; glycerol hjälpämne; butenafinhydroklorid 10 mg aktiv substans; cetylalkohol hjälpämne - butenafin
alerid 10 mg filmdragerad tablett
ucb nordic a/s - cetirizindihydroklorid - filmdragerad tablett - 10 mg - cetirizindihydroklorid 10 mg aktiv substans; laktosmonohydrat hjälpämne - cetirizin
zyrlex 10 mg munsönderfallande tablett
ucb nordic a/s - cetirizindihydroklorid - munsönderfallande tablett - 10 mg - cetirizindihydroklorid 10 mg aktiv substans; betadex hjälpämne - cetirizin